Alternative Go-to-Market and Growth Funding Strategies for Life Sciences

We show founders and key executives in biotech, medtech, pharma, and other life sciences a path to keep more control of their company and realize higher valuations as they go through the fundraising process.

The Democratization of Capital

In the wake of the 2008 financial crisis came not only a tightening of capital, but a tightening of the regulations related to raising capital, particularly for smaller companies. The 2012 JOBS Act changed that, by lowering the reporting and disclosure requirements for small issuers, and by allowing the advertising of securities offerings, greatly expanding the opportunities for companies to offer stock without going through a traditional stock market IPO.

In particular, Regulation A+ provides a vehicle for companies to raise up to $75 million per year from both accredited and non-accredited (“Main Street”) investors. This puts it on a level to provide capital-intensive life sciences companies a viable alternative to venture capital and private equity.

CAPITAL PLANNING VALUATION STRATEGY™ (CPVS)

CPVS is a proprietary process of Medical Funding Professionals that uses company-provided information to develop a custom, proposed pro forma presentation for your Reg A+ offering. The presentation establishes a powerful, forward-looking foundation to effectively implement a company’s capital funding strategies.